A pilot study of irinotecan (CPT-11) as single-agent therapy in patients with locally advanced or metastatic esophageal carcinoma

被引：0
|
作者：
F. Mühr-Wilkenshoff
W. Hinkelbein
I. Ohnesorge
K. J. Wolf
E.-O. Riecken
M. Zeitz
H. Scherübl
机构：
[1] University Hospital Benjamin Franklin,Medical Clinic I
[2] University Hospital Benjamin Franklin,Department of Radiotherapy
[3] University Hospital Benjamin Franklin,Department of Radiology
来源：
International Journal of Colorectal Disease | 2003年 / 18卷
关键词：
Esophageal carcinoma; Irinotecan; CPT-11; Chemotherapy;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：330 / 334
页数：4
相关论文
共 50 条
  • [31] CPT-11/CDDP in advanced cervical cancer. Phase II study of irinotecan combined with cisplatin as neoadjuvant chemotherapy in patients with locally advanced cervical squamous or adenosquamous cell carcinoma
    Sugiyama, T
    Fujiyoshi, K
    Imamura, K
    Ohta, S
    Nishida, T
    Kamura, T
    7TH BIENNIAL MEETING OF THE INTERNATIONAL GYNECOLOGIC CANCER SOCIETY, 1999, : 467 - 471
  • [32] Efficacy and safety of combined radiotherapy with irinotecan (CPT-11), interferon (IFN-alpha-2b) and amifostine in patients with locally advanced cervical carcinoma
    Sarris, G.
    Pectasides, D.
    Kallinoglou, N.
    Vorgias, G.
    Kolliarakis, N.
    Athanasiou, E.
    Beroukas, K.
    Bountouroglou, N.
    Chrysanthou, K.
    Karagiorgis, P.
    EJC SUPPLEMENTS, 2005, 3 (02): : 275 - 275
  • [33] Combination therapy with S-1 and irinotecan (CPT-11) for advanced or recurrent gastric cancer
    Takiuchi, Hiroya
    GASTRIC CANCER, 2009, 12 : 55 - 59
  • [34] Combination therapy with S-1 and irinotecan (CPT-11) for advanced or recurrent gastric cancer
    Hiroya Takiuchi
    Gastric Cancer, 2009, 12 : 55 - 59
  • [35] Capecitabine in combination with two schedules of irinotecan (CPT-11) in advanced colorectal cancer:: A pilot experience.
    Cassata, A
    Alù, M
    Beretta, E
    Ferrario, E
    Lambiase, A
    Comis, S
    Bajetta, E
    ANNALS OF ONCOLOGY, 2000, 11 : 45 - 45
  • [36] Firstline chemotherapy with nedaplatin (CDGP) and irinotecan (CPT-11) for the patients with adenocarcinoma of uterine cervix: A pilot study.
    Yoshida, M
    Tanaka, M
    Kimura, M
    Taguchi, T
    Ogishima, D
    Nojima, M
    Furugen, Y
    Kinoshita, K
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 492S - 492S
  • [37] Phase II trial and pharmacokinetic study of irinotecan (CPT-11) in patients with glioblastoma
    Boige, V
    Raymond, E
    Fabbro, M
    Plazza, J
    Vassal, G
    Risse, ML
    Rodier, JM
    Armand, JP
    ANNALS OF ONCOLOGY, 1998, 9 : 137 - 137
  • [38] Final analysis of irinotecan (CPT-11) and capecitabine (X) as first-line treatment of locally advanced (LA) or metastatic colorectal cancer (MCRC).
    Muñoz, A
    Salud, A
    Alonso, V
    Escudero, P
    Sanz, JJ
    Martín, C
    Rivera, F
    Yubero, A
    García-Girón, C
    López-Vivanco, G
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 272S - 272S
  • [39] Phase II Study of S-1 Combined with Irinotecan (CPT-11) in Patients with Advanced Colorectal Cancer
    Tsunoda, A.
    Yasuda, N.
    Nakao, K.
    Narita, K.
    Watanabe, M.
    Matsui, N.
    Kusano, M.
    ONCOLOGY, 2009, 77 (3-4) : 192 - 196
  • [40] Phase II study of capecitabine single-agent therapy in patients with metastatic renal cell carcinoma
    Pagliaro, Lance C.
    Perez, Cherie A.
    Tu, Shi-Ming
    Daliani, Danal D.
    UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2006, 24 (06) : 487 - 491
12345